On POTP news
<<if the only information that POTP will glean from the interim look is that the trial has not been halted for futility, I wouldn’t expect that to enable new financing on terms the company would consider attractive.>>
No question there. I fully agree!!
That is why I tend to side with your second comment --
<<Normally, only the DSMB’s decision to continue or halt the study based on an interim look is made available to the sponsor of a blinded trial—the actual data from an interim look are normally not made available to the sponsor because doing so could compromise the integrity of subsequent data from the trial. Perhaps, POTP’s trial is an exception to the above, but such exceptions are rare, in my experience.>>
If POTP expects an exception to be made, don't they need to have that in written form from FDA, before the trial is opened for interim analysis??
Note what the CEO said in the PR -- "This analysis will produce the first clinical information on the effects of talabostat in a controlled, randomized trial ..... We felt that it was important to have controlled data at this time in order to properly assist us in our on going strategic and business initiatives."
Not quite sure what to make of this, except they have some agreement with FDA on what kind of data will be released to the company.
Thanks for your comments Dew!
Market Data 
Markets 
AI
